Skip to main content

Refractive Ametropia

0
Pipeline Programs
4
Companies
5
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

Bausch Health
Bausch HealthQUEBEC, Quebec, Canada
2 programs
BL-3100-NBR03 multi-purpose solutionN/A1 trial
REVIVE Contact LensN/A1 trial
Active Trials
NCT05565937Completed295Est. Feb 2024
NCT06053736Completed26Est. Dec 2023
Alcon
AlconFORT WORTH, TX
2 programs
DACP FreshTech contact lensesN/A1 trial
LID015385 soft contact lensesN/A1 trial
Active Trials
NCT04013789Completed79Est. Nov 2019
NCT04085328Completed675Est. Mar 2021
Bausch + Lomb
Bausch + LombNJ - Bridgewater
2 programs
REVIVE Contact LensN/A
BL-3100-NBR03Phase N/A
Johnson & Johnson
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
etafilcon A control lensN/A1 trial
Active Trials
NCT01484028Completed275Est. Feb 2012

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Bausch HealthREVIVE Contact Lens
Bausch HealthBL-3100-NBR03 multi-purpose solution
AlconLID015385 soft contact lenses
AlconDACP FreshTech contact lenses
Johnson & Johnsonetafilcon A control lens

Clinical Trials (5)

Total enrollment: 1,350 patients across 5 trials

NCT06053736Bausch HealthREVIVE Contact Lens

1-Week Dispensing Evaluation of REVIVE™ Toric Soft Contact Lenses

Start: Oct 2023Est. completion: Dec 202326 patients
N/ACompleted
NCT05565937Bausch HealthBL-3100-NBR03 multi-purpose solution

A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting Solution

Start: Apr 2023Est. completion: Feb 2024295 patients
N/ACompleted
NCT04085328AlconLID015385 soft contact lenses

Assessment of an Investigational Frequent Replacement Silicone Hydrogel Lens

Start: Oct 2019Est. completion: Mar 2021675 patients
N/ACompleted
NCT04013789AlconDACP FreshTech contact lenses

Comparison of Two Daily Disposable Lenses

Start: Aug 2019Est. completion: Nov 201979 patients
N/ACompleted
NCT01484028Johnson & Johnsonetafilcon A control lens

Evaluation of the Performance of Two Contact Lenses Compared to a Marketed Lens

Start: Nov 2011Est. completion: Feb 2012275 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.